US equities |
SPCX $144.75 ▼-9.14% MU $856.49 ▼-6.26% NVDA $212.21 ▼-4.40% META $648.85 ▼-6.98% TSLA $374.58 ▼-3.08% AAPL $348.22 ▲+1.23% AMD $507.93 ▼-8.10% SNDK $1,260.93 ▼-8.51%
FinancialContent

Articles published by Entera Bio Ltd.

News headline image
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Correction: Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Announces Second Quarter 2026 Financial Results and Business Updates
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX
News headline image
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
From Entera Bio Ltd.
Via GlobeNewswire
Tickers ENTX